NCT06612580View on ClinicalTrials.gov

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
DRUG

68Ga-AAZTA-NI-093

Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-NI-093. Tracer doses of 68Ga-AAZTA-NI-093 will be used to image lesions of prostate cancer by PET/CT.

Trial Locations (1)

350005

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER